VivoSeq
Neurology

Neuromuscular Block

0

Pipeline Programs

2

Active Trials

0

Companies Involved

Neuromuscular Block is an early-stage landscape with 0 programs across 0 companies.

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

92/100

Attrition Rate

6/100

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

33

clinical trials

Completed22 · 67%
Unknown status7 · 21%
Recruiting2 · 6%
Terminated1 · 3%
Withdrawn1 · 3%

Trial Activity

33 trials

Deep Versus Moderate Neuromuscular Blocking
Recruiting·MMenoufia University·N/A·NCT07485517·88 enrolled
MEP and Neuromuscular Blocker
Completed·GGangnam Severance Hospital·N/A·NCT04768400·100 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)